LEGACY HEALTH	**Legacy Day Treatment Unit Provider's Orders** Adult Ambulatory Infusion Order UBLITUXIMAB (BRIUMVI) INFUSION	**Patient Name:** **Date of Birth:** **Med. Rec. No** (TVC MRN Only):
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE		

Anticipated Start Date: _____ **Patient to follow up with provider on date:** _____
*****This plan will expire after 365 days, unless otherwise specified below*****
Orders expire: _____

Weight: _____kg **Height:** _____cm

Allergies: _____

Diagnosis: _____

Diagnosis Code: _____ (**please include primary and secondary diagnosis codes)**

GUIDELINES FOR PRESCRIBING:

1. Send **FACE SHEET and H&P or most recent chart note.**
2. Hepatitis B (Hep B surface antigen and core antibody total) screening must be completed prior to initiation of treatment and the patient should not be infected. Please send results with order.
3. A Tuberculin test must have been placed and read as negative prior to initiation of treatment (PPD or QuantiFERON Gold blood test). Please send results with order. If result is indeterminate, a follow up chest X-ray must be performed to rule out TB. Please send results with order.
4. Serious, including life-threatening and fatal infections, have occurred. Delay ublituximab administration in patients with an active infection until the infection is resolved.
5. Vaccination with live attenuated or live vaccines is not recommended during treatment with ublituximab and after discontinuation, until B-cell repletion.
6. Monitor the level of immunoglobulins at the beginning, during, and after discontinuation of treatment with ublituximab, until B-cell repletion, and especially when recurrent serious infections are suspected. Consider discontinuing ublituximab in patients with serious opportunistic or recurrent serious infections, and if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.
7. May cause fetal harm. Advise patients of childbearing potential of the potential risk to a fetus and to use effective contraception during treatment and for at least 6 months after stopping ublituximab.

PRE-SCREENING (orders must be placed in TVC Epic by ordering provider if TVC provider):

- ☐ Hepatitis B surface antigen and core antibody test results scanned with orders.
- ☐ Tuberculin skin test or QuantiFERON Gold blood test results scanned with orders.
- ☐ Chest X-Ray result scanned with orders if TB test result is indeterminate.
- ☐ IgG level test results scanned with orders.
- ☐ IgM level test results scanned with orders.

LABS (orders must be placed in TVC Epic by ordering provider if TVC provider):

- ☐ CBC with differential, Routine, ONCE, every visit
- ☐ Complete Metabolic Panel, Routine, ONCE, every visit
- ☐ IgG, Routine, ONCE, every visit
- ☐ IgM, Routine, ONCE, every visit
- ☐ CD19, Routine, ONCE, every visit
- ☐ HCG Qual, Urine, Routine, ONCE, every visit, for patients of childbearing potential

LEGACY HEALTH	**Legacy Day Treatment Unit Provider's Orders** Adult Ambulatory Infusion Order UBLITUXIMAB (BRIUMVI) INFUSION	**Patient Name:** **Date of Birth:** **Med. Rec. No** (TVC MRN Only):
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE		

NURSING ORDERS (TREATMENT PARAMETERS):

1. TREATMENT PARAMETER – Hold treatment and contact provider if Hepatitis B surface antigen or core antibody total test result is positive, TB test result is positive, or if screening has not been performed.
2. TREATMENT PARAMETER – Hold treatment and contact provider if there is an active infection.
3. TREATMENT PARAMETER – Hold treatment and contact provider if HCG urine test is positive.
4. TREATMENT PARAMETER – Hold treatment and contact provider if IgG or IgM levels are low.
5. **First infusion (150 mg):** Initiate infusion at 10 mL/hour for 30 minutes; if tolerated, increase to 20 mL/hour for 30 minutes; if tolerated, increase to 35 mL/hour for 60 minutes; if tolerated, increase to 100 mL/hour for the remainder of the infusion. Infusion duration: 4 hours.
6. **Subsequent infusions (450 mg):** Initiate infusion at 100 mL/hour for 30 minutes; if tolerated, increase to 400 mL/hour for the remainder of the infusion. Infusion duration: 1 hour.
7. Monitor for infusion reactions during infusion and observe for at least 1 hour after completion of first two infusions. Incidence is highest within 24 hours of the first infusion. Inform patients that infusion reactions may occur up to 24 hours after each infusion.
8. Mild to moderate reactions: Reduce infusion rate to 50% of the rate at which the reaction occurred. If tolerated for at least 30 minutes, return to original infusion rate titration until completion of infusion.
9. Severe reactions: Immediately stop infusion and administer supportive treatment. Following complete symptom resolution, restart infusion rate at 50% the rate at which the onset of the infusion reaction occurred. If tolerated, may return to original infusion rate titration as appropriate until completion of infusion.
10. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)
Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s).

- ☐ acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
- ☐ diphenhydrAMINE (BENADRYL) capsule, 50 mg, oral, ONCE, every visit.
  Give either loratadine or diphenhydrAMINE, not both.
- ☐ loratadine (CLARITIN) tablet, 10 mg, oral, ONCE AS NEEDED if diphenhydrAMINE is not given, every visit. **Give either loratadine or diphenhydrAMINE, not both.**
- ☐ methylPREDNISolone sodium succinate (SOLU-MEDROL), 125 mg, intravenous, ONCE, every visit

MEDICATIONS:

- ☑ Ublituximab (BRIUMVI), 150 mg in sodium chloride 0.9%, intravenous, ONCE on day 1, followed by 450 mg in sodium chloride 0.9%, intravenous, ONCE 2 weeks later. Subsequent doses of 450 mg are administered ONCE every 24 weeks (beginning 24 weeks after the first dose of 150 mg).

LEGACY HEALTH	**Legacy Day Treatment Unit Provider's Orders** Adult Ambulatory Infusion Order UBLITUXIMAB (BRIUMVI) INFUSION	**Patient Name:** **Date of Birth:** **Med. Rec. No** (TVC MRN Only):
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE		

HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION - If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Refer to LH policy 906.6606 Initiation of Emergency Measures for Adult Oncology, Radiation Oncology and Infusion Clinic Patients
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

Please check the appropriate box for the patient's preferred clinic location:

☐ **Legacy Day Treatment Unit – The Vancouver Clinic Building**
A department of Salmon Creek Medical Center
700 NE 87th Avenue, Suite 360
Vancouver, WA 98664
Phone number: 360-896-7070
Fax number: 360-487-5773

☐ **Legacy Emanuel Day Treatment Unit**
A department of Emanuel Medical Center
501 N Graham Street, Suite 540
Portland, OR 97227
Phone number: 503-413-4608
Fax number: 503-413-4887

☐ **Legacy Salmon Creek Day Treatment Unit**
Legacy Salmon Creek Medical Center
2121 NE 139th Street, Suite 110
Vancouver, WA 98686
Phone number: 360-487-1750
Fax number: 360-487-5773

☐ **Legacy STEPS Clinic**
A department of Silverton Medical Center
Legacy Woodburn Health Center
1475 Mt Hood Ave
Woodburn, OR 97071
Phone number: 503-982-1280
Fax number: 503-225-8723

Provider signature: _____ **Date/Time:** _____

Printed Name: _____ **Phone:** _____ **Fax:** _____

Organization/Department: _____